An Intestinal Th17 Subset is Associated with Inflammation in Crohn's Disease and Activated by Adherent-invasive Escherichia coli.

"data availability the rna sequencing data of intestinal and circulating ccr6 + t cell subsets have been deposited in the arrayexpress [ https://www ebi ac uk/biostudies/arrayexpress ] (accession no. e-mtab-13178). data availability the rna sequencing data of intestinal and circulating ccr6 + t cell subsets have been deposited in the arrayexpress [ https://www ebi ac uk/biostudies/arrayexpress ] (accession no. e-mtab-13178"

"Conflict of Interest MV served as a consultant to Abbvie, MSD, Takeda, Janssen-Cilag, and Celgene; and received lecturer fees from Abbvie, Ferring, Takeda, MSD, Janssen-Cilag, and Zambon. FC has served as consultant to Mundipharma, AbbVie, MSD, Takeda, Janssen, Roche, and Celgene; received lecture fees from AbbVie, Ferring, Takeda, Allergy Therapeutics, and Janssen; and received unrestricted research grants from Giuliani, SOFAR, MS&D, Takeda, Pfizer and AbbVie. All other authors have no conflicts of interest to declare."

"Funding This study was financially supported by the Italy’s Ministry of Health [Young Researchers ‘Giovani Ricercatori’ Program Ref. No. GR-2011-02352001] to FC and MP, by Italian Ministry of Health [GR-2016-02361741] to FC, and by Cariplo Foundation-Biomedical Research Conducted by Young Researchers [GR-2017–0816] to MP and FC. J G is supported by Associazione Italiana per la Ricerca sul Cancro [AIRC, IG 2019 23581]."

"All IBD patients included in this study were categorised/classified according to clinical and endoscopic disease activity, using the Harvey–Bradshaw index [HBI] and the Simple Endoscopic Score [SES-CD] for CD patients or Mayo score for UC patients []. For some experiments, biopsies were taken before and after treatment with biologic drugs, namely infliximab and risankizumab []. Infliximab was given intravenously at 5 mg/kg at Weeks 0, 2, and 6 and then every 8 weeks. Risankizumab was given intravenously at a fixed dose of 600 mg at Weeks 0, 4, and 8, and then subcutaneously at a dose of 360 mg every 8 weeks. The clinical characteristics and therapies of all IBD and non-IBD patients are listed in . The CD patients were either ileal or ileocolonic. The study was registered with Eudract ref. no. 2015-003270-32 and the institutional review board approved the study with permission no. 566_2015 quinquies, approved by the local ethics committee [Milano Area B, code 128_2018bis], and was performed in accordance with the Declaration of Helsinki protocols."